World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
95
Citations
41702
World Ranking
9930
National Ranking
140

Overview

Aleix Prat is affiliated with the University of Barcelona in Spain. Their research output spans several specialized fields within medicine and biochemistry, genetics, and molecular biology, with a particular focus on oncology.

The primary subfields of study in their work include:

  • Oncology
  • Pulmonary and Respiratory Medicine
  • Cancer Research
  • Genetics
  • Radiology, Nuclear Medicine and Imaging

Key research topics covered in their publications involve:

  • Advanced Breast Cancer Therapies
  • HER2/EGFR in Cancer Research
  • Breast Cancer Treatment Studies
  • Cancer Treatment and Pharmacology
  • Cancer Immunotherapy and Biomarkers
  • Cancer Genomics and Diagnostics
  • Monoclonal and Polyclonal Antibodies Research

Among Aleix Prat's recent papers are:

  • "Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer" (2022), published in New England Journal of Medicine
  • "Immune-related adverse events of checkpoint inhibitors" (2020), published in Nature Reviews Disease Primers
  • "Customizing local and systemic therapies for women with early breast cancer: the St. Gallen International Consensus Guidelines for treatment of early breast cancer 2021" (2021), published in Annals of Oncology
  • "Clinical, pathological, and PAM50 gene expression features of HER2-low breast cancer" (2021), published in npj Breast Cancer
  • "Frequency and spectrum of PIK3CA somatic mutations in breast cancer" (2020), published in Breast Cancer Research

Frequent co-authors who have collaborated extensively with Aleix Prat include:

  • Tomás Pascual
  • Fara Brasó-Maristany
  • Laia Paré
  • María Vidal
  • Patricia Galván

The main venues for publishing Aleix Prat's work encompass:

  • Cancer Research
  • Annals of Oncology
  • UNC Libraries
  • Journal of Clinical Oncology
  • ESMO Open

Best Publications

  • Comprehensive molecular portraits of human breast tumours

    Daniel C. Koboldt;Robert S. Fulton;Michael D. McLellan;Heather Schmidt

  • Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer

    Aleix Prat;Joel S Parker;Olga Karginova;Cheng Fan

  • Deconstructing the molecular portraits of breast cancer.

    Aleix Prat;Charles M. Perou

  • Immune-related adverse events of checkpoint inhibitors.

    Manuel Ramos-Casals;Julie R. Brahmer;Margaret K. Callahan;Margaret K. Callahan;Alejandra Flores-Chávez

  • Clinical implications of the intrinsic molecular subtypes of breast cancer.

    Aleix Prat;Aleix Prat;Estela Pineda;Barbara Adamo;Barbara Adamo;Patricia Galván

  • Endocrine-therapy-resistant ESR1 variants revealed by genomic characterization of breast-cancer-derived xenografts.

    Shunqiang Li;Dong Shen;Jieya Shao;Robert Crowder

  • Prognostic Significance of Progesterone Receptor–Positive Tumor Cells Within Immunohistochemically Defined Luminal A Breast Cancer

    Aleix Prat;Maggie Chon U. Cheang;Miguel Martín;Joel S. Parker

  • Molecular Characterization of Basal-Like and Non-Basal-Like Triple-Negative Breast Cancer

    Aleix Prat;Barbara Adamo;Maggie C.U. Cheang;Carey K. Anders

  • Randomized Phase II Neoadjuvant Comparison Between Letrozole, Anastrozole, and Exemestane for Postmenopausal Women With Estrogen Receptor–Rich Stage 2 to 3 Breast Cancer: Clinical and Biomarker Outcomes and Predictive Value of the Baseline PAM50-Based Intrinsic Subtype—ACOSOG Z1031

    Matthew J. Ellis;Vera J. Suman;Jeremy Hoog;Li Lin

  • PI3K Inhibition Impairs BRCA1/2 Expression and Sensitizes BRCA-Proficient Triple-Negative Breast Cancer to PARP Inhibition

    Yasir H. Ibrahim;Celina García-García;Violeta Serra;Lei He

  • Customizing local and systemic therapies for women with early breast cancer: the St. Gallen International Consensus Guidelines for treatment of early breast cancer 2021.

    H J Burstein;G Curigliano;B Thürlimann;W P Weber

  • A Renewable Tissue Resource of Phenotypically Stable, Biologically and Ethnically Diverse, Patient-Derived Human Breast Cancer Xenograft Models

    Xiaomei Zhang;Sofie Claerhout;Aleix Prat;Lacey E. Dobrolecki

  • 進行性乳癌のためのESO-ESMO国際コンセンサスガイドライン第四版(ABC 4)

    F Cardoso;E Senkus;A Costa;E Papadopoulos

  • Clinical, pathological, and PAM50 gene expression features of HER2-low breast cancer.

    Francesco Schettini;Francesco Schettini;Nuria Chic;Nuria Chic;Fara Brasó-Maristany;Fara Brasó-Maristany;Laia Paré

  • USP15 stabilizes TGF-β receptor I and promotes oncogenesis through the activation of TGF-β signaling in glioblastoma

    Pieter J A Eichhorn;Laura Rodón;Alba Gonzàlez-Juncà;Annette Dirac

  • PI3K inhibition results in enhanced estrogen receptor function and dependence in hormone receptor–positive breast cancer

    Ana Bosch;Zhiqiang Li;Anna Bergamaschi;Haley Ellis

  • PAM50 Breast Cancer Subtyping by RT-qPCR and Concordance with Standard Clinical Molecular Markers

    Roy R L Bastien;Álvaro Rodríguez-Lescure;Mark T W Ebbert;Aleix Prat;Aleix Prat

  • Immune-Related Gene Expression Profiling After PD-1 Blockade in Non–Small Cell Lung Carcinoma, Head and Neck Squamous Cell Carcinoma, and Melanoma

    Aleix Prat;Alejandro Navarro;Laia Paré;Noemí Reguart

  • Genomic aberrations in the FGFR pathway: opportunities for targeted therapies in solid tumors

    R. Dienstmann;J. Rodon;A. Prat;J. Perez-Garcia

  • Cyclin E amplification/overexpression is a mechanism of trastuzumab resistance in HER2+ breast cancer patients

    Maurizio Scaltriti;Pieter J. Eichhorn;Javier Cortés;Ludmila Prudkin

Frequent Co-Authors

Charles M. Perou
Charles M. Perou University of North Carolina at Chapel Hill
Javier Cortes
Javier Cortes Vall d'Hebron Hospital Universitari
Paolo Nuciforo
Paolo Nuciforo Vall d´Hebron Institute of Oncology
Joel S. Parker
Joel S. Parker University of North Carolina at Chapel Hill
José Baselga
José Baselga Memorial Sloan Kettering Cancer Center
Lisa A. Carey
Lisa A. Carey University of North Carolina at Chapel Hill
Maggie C.U. Cheang
Maggie C.U. Cheang Institute of Cancer Research
Josep Tabernero
Josep Tabernero Vall d´Hebron Institute of Oncology
Matthew J. Ellis
Matthew J. Ellis Baylor College of Medicine
Olufunmilayo I. Olopade
Olufunmilayo I. Olopade University of Chicago

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

For those interested in healthcare but considering alternatives to a traditional US medical degree, online programs offer flexible and accelerated options. Aspiring nurses or nurse practitioners can choose from pathways tailored to different experience levels and goals.

If you already hold a nursing license and want to advance quickly, consider the shortest dnp programs online. These Doctor of Nursing Practice (DNP) programs are designed to help working professionals reach the highest level of nursing practice in less time.

Those looking for an even faster route to a clinical doctorate can explore a 1 year dnp program online, which offers rapid progression for qualified nurses.

For individuals new to healthcare, an lpn program provides a quick way to enter the workforce as a Licensed Practical Nurse. LPN programs can often be completed online and lead to jobs in various healthcare settings.

Those aiming to specialize in mental health can explore the shortest pmhnp program to become a Psychiatric Mental Health Nurse Practitioner. These accelerated degrees prepare graduates for high-demand careers addressing mental wellness.

Best Scientists Citing Aleix Prat

Trending Scientists